BACKGROUND AND OBJECTIVES: The relationship between iodine intake and effects of antithyroid drugs (ATD) for Graves' disease, especially in iodine-deficient areas, has been demonstrated in many studies. However, it was not clear how chronic high iodine intake influenced the effectiveness of ATD in an iodine-replete area. This study aimed to clarify the effect of iodine intake on clinical outcomes of Graves' disease after discontinuation of ATD in Korea, an iodine-replete area. METHODS: A total of 142 patients with Graves' disease who visited the outpatient clinic regularly and stopped their ATD between October 2011 and April 2013 were enrolled in our study. Urinary iodine concentration (UIC) was measured just before and after the discontinuation of ATD. RESULTS: Median UIC was not significantly different between the remission and relapse groups, as well as among the four treatment groups (group 1, remission after initial treatment; group 2, remission after repeated treatment; group 3, early relapse within a year; group 4, late relapse after a year). Remission rates did not show a significant difference between the excessive iodine intake (UIC ≥300 μg/l) and average iodine intake groups (UIC <300 μg/l). CONCLUSIONS: The present study suggests that excessive iodine intake does not have an effect on the clinical outcomes of Graves' disease in an iodine-replete area, and therefore diet control with iodine restriction might not be necessary in the management of Graves' disease.
BACKGROUND AND OBJECTIVES: The relationship between iodine intake and effects of antithyroid drugs (ATD) for Graves' disease, especially in iodine-deficient areas, has been demonstrated in many studies. However, it was not clear how chronic high iodine intake influenced the effectiveness of ATD in an iodine-replete area. This study aimed to clarify the effect of iodine intake on clinical outcomes of Graves' disease after discontinuation of ATD in Korea, an iodine-replete area. METHODS: A total of 142 patients with Graves' disease who visited the outpatient clinic regularly and stopped their ATD between October 2011 and April 2013 were enrolled in our study. Urinary iodine concentration (UIC) was measured just before and after the discontinuation of ATD. RESULTS: Median UIC was not significantly different between the remission and relapse groups, as well as among the four treatment groups (group 1, remission after initial treatment; group 2, remission after repeated treatment; group 3, early relapse within a year; group 4, late relapse after a year). Remission rates did not show a significant difference between the excessive iodine intake (UIC ≥300 μg/l) and average iodine intake groups (UIC <300 μg/l). CONCLUSIONS: The present study suggests that excessive iodine intake does not have an effect on the clinical outcomes of Graves' disease in an iodine-replete area, and therefore diet control with iodine restriction might not be necessary in the management of Graves' disease.
Entities:
Keywords:
Antithyroid drug; Graves’ disease; Hyperthyroidism; Iodine; Korea
Authors: Zubair Baloch; Pierre Carayon; Bernard Conte-Devolx; Laurence M Demers; Ulla Feldt-Rasmussen; Jean-François Henry; Virginia A LiVosli; Patricia Niccoli-Sire; Rhys John; Jean Ruf; Peter P A Smyth; Carole A Spencer; Jan R Stockigt Journal: Thyroid Date: 2003-01 Impact factor: 6.568
Authors: Pornpoj Pramyothin; Angela M Leung; Elizabeth N Pearce; Alan O Malabanan; Lewis E Braverman Journal: N Engl J Med Date: 2011-12-01 Impact factor: 91.245
Authors: Ji Hyun Lee; Ok Ja Ji; Min Jung Song; Hyung Doo Park; Hee Kyung Kim; Sun Wook Kim; Jae Hoon Chung; Soo Youn Lee Journal: Korean J Lab Med Date: 2010-08
Authors: P Macours; J C Aubry; B Hauquier; J M Boeynaems; S Goldman; R Moreno-Reyes Journal: J Trace Elem Med Biol Date: 2008-06-05 Impact factor: 3.849
Authors: Vishnu Sundaresh; Juan P Brito; Zhen Wang; Larry J Prokop; Marius N Stan; Mohammad H Murad; Rebecca S Bahn Journal: J Clin Endocrinol Metab Date: 2013-07-03 Impact factor: 5.958
Authors: H Tamai; T Nakagawa; O Fukino; N Ohsako; R Shinzato; H Suematsu; K Kuma; F Matsuzuka; S Nagataki Journal: Ann Intern Med Date: 1980-04 Impact factor: 25.391
Authors: Suyeon Park; Eyun Song; Hye-Seon Oh; Mijin Kim; Min Ji Jeon; Won Gu Kim; Tae Yong Kim; Young Kee Shong; Doo Man Kim; Won Bae Kim Journal: Endocrine Date: 2019-06-24 Impact factor: 3.633